Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone intravitreal implant - Interface Biologics/Ripple Therapeutics

Next Previous
Drug Profile

Dexamethasone intravitreal implant - Interface Biologics/Ripple Therapeutics

Alternative Names: CSP-814; IBE-814; IBE-814 IVT Implant

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Interface Biologics
  • Developer Interface Biologics; Ripple Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Retinal vein occlusion
  • Preclinical Retinal oedema; Retinitis pigmentosa
  • No development reported Uveitis

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for preclinical development in Uveitis in Canada (Intravitreous, Implant)
  • 15 Mar 2024 Ripple Therapeutics completes phase-II clinical trials in Diabetic macular oedema and Retinal vein occlusion in Canada, Hong Kong, Australia and New Zealand (Intravitreous) (NCT04576689)
  • 17 Jul 2023 Preclinical trials in Retinal oedema in Canada (Intravitreous) (Ripple Therapeutics pipeline, July 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top